Secures Two-Year Contract to Continue to
Supply Italy with high-quality medical cannabis
NYSE: ACB TSX:ACB
EDMONTON, July 18, 2019 /CNW/ - Aurora Cannabis Inc.
("Aurora" or the "Company") (NYSE: ACB) (TSX: ACB), the Canadian
company defining the future of cannabis worldwide, announced today
that the Company has been selected as the only winner of the
Italian government's public tender to supply medical cannabis in
Italy. The supply contract is
expected to be signed in September
2019.
The tender saw five companies participate, with Aurora selected
as the sole winner of three lots to supply the Italian market,
which is one of the most strictly regulated medical cannabis
markets in the world. The decision will see Aurora continue to
supply the Italian market with medical cannabis, as it has done for
the past 15 months, further to winning the first ever tender there
in January 2018. All submissions from
competing cannabis companies were disqualified because they were
unable to meet the stringent requirements of the tender.
Aurora will supply a minimum of 400 kg of medical cannabis over
the two-year contract with the cannabis coming from its
Canadian EU GMP certified facilities and imported to Italy through Aurora Deutschland, its
wholly-owned European subsidiary. The cannabis will be sold to
Agenzia Industrie Difesa (an agency of the Italian Ministry of
Defense) for distribution to local pharmacies, who dispense
directly to patients.
"We're committed to building a successful, long-term medical
cannabis market in Italy," said
Neil Belot, Aurora's Chief Global
Business Development Officer. "We want to continue to build our
connection with patients and pharmacies in the Italian market, who
have come to know and appreciate our products over most of the past
two years. I'm extremely proud of our team. This win reflects our
ability to navigate complex international regulations and work with
governments around the world to establish ourselves as a trusted
partner."
Axel Gille, Managing Director of
Aurora Deutschland GmbH, added, "The well-being of our patients is
our top priority and we're dedicated to ensuring they have access
to a consistent supply of safe, high-quality medical cannabis. We
look forward to expanding our presence in Italy and continuing to work with other
international regulators to ensure patients around the world have
access to our high-quality medical cannabis."
About Aurora
Headquartered in Edmonton, Alberta,
Canada with funded capacity in excess of 625,000 kg per
annum and sales and operations in 25 countries across five
continents, Aurora is one of the world's largest and leading
cannabis companies. Aurora is vertically integrated and
horizontally diversified across every key segment of the value
chain, from facility engineering and design to cannabis breeding
and genetics research, cannabis and hemp production, derivatives,
high value-add product development, home cultivation, wholesale and
retail distribution.
Highly differentiated from its peers, Aurora has established a
uniquely advanced, consistent and efficient production strategy,
based on purpose-built facilities that integrate leading-edge
technologies across all processes, defined by extensive automation
and customization, resulting in the massive scale production of
high-quality consistent product. Intended to be replicable and
scalable globally, our production facilities are designed to
produce cannabis of significant scale, with high quality,
industry-leading yields, and low per gram production costs. Each of
Aurora's facilities is built to meet European Union Good
Manufacturing Practices ("EU GMP") standards. Certification has
been granted to Aurora's first production facility in Mountain View
County, the MedReleaf Markham facility, and its wholly owned
European medical cannabis distributor Aurora Deutschland. All
Aurora facilities are designed and built to the EU GMP
standard.
In addition to the Company's rapid organic growth and strong
execution on strategic M&A, which to date includes 17 wholly
owned subsidiary companies – MedReleaf, CanvasRX, Peloton
Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator,
BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics,
Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC
Labs, Whistler, and Chemi Pharmaceutical – Aurora is distinguished
by its reputation as a partner and employer of choice in the global
cannabis sector, having invested in and established strategic
partnerships with a range of leading innovators, including: Radient
Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV:
HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc.
(CSE: MWM), Choom Holdings Inc. (CSE: CHOO), CTT Pharmaceuticals
(OTCC: CTTH), Alcanna Inc. (TSX: CLIQ), High Tide Inc. (CSE: HITI),
EnWave Corporation (TSXV: ENW), Capcium Inc. (private), Evio Beauty
Group (private), and Wagner Dimas (private).
Aurora's Common Shares trade on the TSX and NYSE under the
symbol "ACB", and are a constituent of the S&P/TSX Composite
Index.
For more information about Aurora, please visit our investor
website, investor.auroramj.com
Terry Booth, CEO
Aurora Cannabis Inc.
Forward looking statements
This news release includes statements containing certain
"forward-looking information" within the meaning of applicable
securities law ("forward-looking statements"), including, but not
limited to, statements with respect to the performance of the
Company. Forward-looking statements are frequently characterized by
words such as "plan", "continue", "expect", "project", "intend",
"believe", "anticipate", "estimate", "may", "will", "potential",
"proposed" and other similar words, or statements that certain
events or conditions "may" or "will" occur, and include, but are
not limited to, the quantity of cannabis that the Company supplies
to Italy and the distribution
channels for the cannabis that is supplied. These statements are
only predictions. Various assumptions were used in drawing the
conclusions or making the projections contained in the
forward-looking statements throughout this news release.
Forward-looking statements are based on the opinions and estimates
of management at the date the statements are made, and are subject
to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from
those projected in the forward-looking statements. The Company is
under no obligation, and expressly disclaims any intention or
obligation, to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as expressly required by applicable law.
Neither TSX, NYSE nor their applicable Regulation Services
Providers (as that term is defined in the policies of the Toronto
Stock Exchange and New York Stock Exchange) accept responsibility
for the adequacy or accuracy of this release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aurora-cannabis-selected-as-sole-winner-in-italian-cannabis-tender-300887305.html
SOURCE Aurora Cannabis Inc.